Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 3 60 kDa
|
Escherichia coli
|
0.1
%
|
|
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 4 49 kDa
|
Escherichia coli
|
100.0
%
|
|
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 1a 90 kDa
|
Escherichia coli
|
0.1
%
|
|
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 1b 90 kDa
|
Escherichia coli
|
0.5
%
|
|
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 2 66 kDa
|
Escherichia coli
|
100.0
%
|
|
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as Penicillin-binding protein 5/6 40 kDa
|
Escherichia coli
|
100.0
%
|
|
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP1 by competitive binding assay
|
Staphylococcus aureus
|
0.25
ug.mL-1
|
|
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP1 by competitive binding assay
|
Staphylococcus aureus
|
2.0
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP1 by competitive binding assay
|
Staphylococcus aureus
|
0.5
ug.mL-1
|
|
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP1 by competitive binding assay
|
Staphylococcus aureus
|
4.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP1 by competitive binding assay
|
Staphylococcus aureus
|
1.0
ug.mL-1
|
|
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP1 by competitive binding assay
|
Staphylococcus aureus
|
16.0
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP2 by competitive binding assay
|
Staphylococcus aureus
|
0.25
ug.mL-1
|
|
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2 by competitive binding assay
|
Staphylococcus aureus
|
0.5
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2 by competitive binding assay
|
Staphylococcus aureus
|
0.25
ug.mL-1
|
|
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2 by competitive binding assay
|
Staphylococcus aureus
|
1.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2 by competitive binding assay
|
Staphylococcus aureus
|
1.0
ug.mL-1
|
|
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2 by competitive binding assay
|
Staphylococcus aureus
|
2.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2a by competitive binding assay
|
Staphylococcus aureus
|
128.0
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2a by competitive binding assay
|
Staphylococcus aureus
|
1.0
ug.mL-1
|
|
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2a by competitive binding assay
|
Staphylococcus aureus
|
128.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2a by competitive binding assay
|
Staphylococcus aureus
|
2.0
ug.mL-1
|
|
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2a by competitive binding assay
|
Staphylococcus aureus
|
0.25
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP3 by competitive binding assay
|
Staphylococcus aureus
|
1.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP3 by competitive binding assay
|
Staphylococcus aureus
|
0.25
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP3 by competitive binding assay
|
Staphylococcus aureus
|
0.25
ug.mL-1
|
|
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP3 by competitive binding assay
|
Staphylococcus aureus
|
2.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP3 by competitive binding assay
|
Staphylococcus aureus
|
1.0
ug.mL-1
|
|
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP3 by competitive binding assay
|
Staphylococcus aureus
|
1.0
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP4 by competitive binding assay
|
Staphylococcus aureus
|
8.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP4 by competitive binding assay
|
Staphylococcus aureus
|
128.0
ug.mL-1
|
|
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP4 by competitive binding assay
|
Staphylococcus aureus
|
128.0
ug.mL-1
|
|
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP4 by competitive binding assay
|
Staphylococcus aureus
|
128.0
ug.mL-1
|
|
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP4 by competitive binding assay
|
Staphylococcus aureus
|
128.0
ug.mL-1
|
|
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1A by competitive binding assay
|
Streptococcus pneumoniae
|
0.1
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1A by competitive binding assay
|
Streptococcus pneumoniae
|
0.125
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1A by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1A by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1B by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1B by competitive binding assay
|
Streptococcus pneumoniae
|
8.0
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1B by competitive binding assay
|
Streptococcus pneumoniae
|
4.0
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1B by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2X by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2X by competitive binding assay
|
Streptococcus pneumoniae
|
1.0
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2X by competitive binding assay
|
Streptococcus pneumoniae
|
4.0
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2X by competitive binding assay
|
Streptococcus pneumoniae
|
0.1
ug.mL-1
|
|
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2A by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2A by competitive binding assay
|
Streptococcus pneumoniae
|
0.5
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2A by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2A by competitive binding assay
|
Streptococcus pneumoniae
|
0.25
ug.mL-1
|
|
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2B by competitive binding assay
|
Streptococcus pneumoniae
|
32.0
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2B by competitive binding assay
|
Streptococcus pneumoniae
|
16.0
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2B by competitive binding assay
|
Streptococcus pneumoniae
|
16.0
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2B by competitive binding assay
|
Streptococcus pneumoniae
|
4.0
ug.mL-1
|
|
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP3 by competitive binding assay
|
Streptococcus pneumoniae
|
0.1
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP3 by competitive binding assay
|
Streptococcus pneumoniae
|
0.1
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP3 by competitive binding assay
|
Streptococcus pneumoniae
|
0.1
ug.mL-1
|
|
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP3 by competitive binding assay
|
Streptococcus pneumoniae
|
0.1
ug.mL-1
|
|
Bactericidal activity against Escherichia coli ATCC 25922 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs
|
Escherichia coli
|
10.0
%
|
|
Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs
|
Pseudomonas aeruginosa
|
10.0
%
|
|
Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-30 using cephalothin as reporter substrate
|
Escherichia coli
|
300.0
nM
|
|
Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-2 using cephalothin as reporter substrate
|
Escherichia coli
|
5.0
nM
|
|
Activity of Acinetobacter baumannii ADC-33 beta-lactamase
|
Acinetobacter baumannii
|
500.0
nM
|
|
TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells
|
None
|
290.0
nM
|
|
Antimicrobial activity against Candida albicans ATCC 90028 assessed as inhibition of microbial growth by CLSI based method
|
Candida albicans
|
200.0
nM
|
|
Antimicrobial activity against Aspergillus fumigatus ATCC 90906 assessed as inhibition of microbial growth by CLSI based method
|
Aspergillus fumigatus
|
200.0
nM
|
|
Antimicrobial activity against Cryptococcus neoformans ATCC 90113 assessed as inhibition of microbial growth by CLSI based method
|
Cryptococcus neoformans
|
200.0
nM
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of microbial growth by CLSI based method
|
Staphylococcus aureus
|
30.0
nM
|
|
Antimicrobial activity against Escherichia coli ATCC 35218 assessed as inhibition of microbial growth by CLSI based method
|
Escherichia coli
|
100.0
nM
|
|
Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of microbial growth by CLSI based method
|
Pseudomonas aeruginosa
|
30.0
nM
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
4.74
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.11
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.11
%
|
|